肠黏膜通透性改变与炎症性肠病关系的研究进展

孙博云; 王师英; 胡鸿毅

doi:10.3969/j.issn.1671-038X.2016.11.21

肠黏膜通透性改变与炎症性肠病关系的研究进展

- 上海中医药大学附属龙华医院脾胃病科, 上海 200032
基金项目:
国家自然科学基金项目(No:81373616)

详细信息

作者简介:
孙博云,男,硕士研究生,主要从事中医药防治炎症性肠病研究

通讯作者: 胡鸿毅,E-mail:hongyihu2003@aliyun.com

中图分类号: R57

收稿日期: 2016-06-15

Corresponding author: HU Hong-yi, E-mail: hongyihu2003@aliyun.com

Received Date: 15 June 2016

摘要

- 黏膜通透性 /
- 肠黏膜屏蔽功能 /
- 炎症性肠病

HTML全文

参考文献(33)

[1]	YASHIRO M.Ulcerative colitis-associated colorectal cancer[J].World J Gastroenterol,2014,20:16389-16397.
[2]	EDELBLUM K L,TURNER J R.The tight junction in inflammatory disease:communication breakdown[J].Curr Opin Pharmacol,2009,9:715-720.
[3]	BISCHOFF S C,BARBARA G,BUURMAN W,et al.Intestinal permeability--a new target for disease prevention and therapy[J].BMC Gastroenterol,2014,14:189-189.
[4]	ZEISSIG S,BURGEL N,GUNZEL D,et al.Changes in expression and distribution of claudin 2,5and 8lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease[J].Gut,2007,56:61-72.
[5]	SCHULZKE J D,BOJARSKI C,ZEISSIG S,et al.Disrupted barrier function through epithelial cell apoptosis[J].Ann N Y Acad Sci,2006,1072:288-299.
[6]	MANKERTZ J,SCHULZKE J D.Altered permeability in inflammatory bowel disease:pathophysiology and clinical implications[J].Curr Opin Gastroenterol,2007,23:379-383.
[7]	TAKEUCHI K,MAIDEN L,BJARNASON I.Genetic aspects of intestinal permeability in inflammatory bowel disease[J].Novartis Found Symp,2004,263:151-158;discussion 159-163,211-218.
[8]	OLSON T S,REUTER B K,SCOTT K G,et al.The primary defect in experimental ileitis originates from a nonhematopoietic source[J].J Exp Med,2006,203:541-552.
[9]	VETRANO S,DANESE S.The role of JAM-A in inflammatory bowel disease:unrevealing the ties that bind[J].Ann N Y Acad Sci,2009,1165:308-313.
[10]	SHIH D Q,TARGAN S R.Insights into IBD Pathogenesis[J].Curr Gastroenterol Rep,2009,11:473-480.
[11]	MANKERTZ J,AMASHEH M,KRUG S M,et al.TNFalpha up-regulates claudin-2expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling[J].Cell Tissue Res,2009,336:67-77.
[12]	AL-SADI R,GUO S,YE D,et al.TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1[J].Am J Pathol,2013,183:1871-1884.
[13]	BOUMA G,STROBER W.The immunological and genetic basis of inflammatory bowel disease[J].Nat Rev Immunol,2003,3:521-533.
[14]	BRUEWER M,UTECH M,IVANOV A I,et al.Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process[J].FASEB J,2005,19:923-933.
[15]	UTECH M,IVANOV A I,SAMARIN S N,et al.Mechanism of IFN-gamma-induced endocytosis of tight junction proteins:myosin II-dependent vacuolarization of the apical plasma membrane[J].Mol Biol Cell,2005,16:5040-5052.
[16]	BOWIE R V,DONATELLO S,LYES C,et al.Lipid rafts are disrupted in mildly inflamed intestinal microenvironments without overt disruption of the epithelial barrier[J].Am J Physiol Gastrointest Liver Physiol,2012,302:G781-G793.
[17]	LAUKOETTER M G,BRUEWER M,NUSRAT A.Regulation of the intestinal epithelial barrier by the apical junctional complex[J].Curr Opin Gastroenterol,2006,22:85-89.
[18]	LIU X,XU J,MEI Q,et al.Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice[J].Dig Dis Sci,2013,58:107-114.
[19]	LAPOINTE T K,BURET A G.Interleukin-18facilitates neutrophil transmigration via myosin light chain kinase-dependent disruption of occludin,without altering epithelial permeability[J].Am J Physiol Gastrointest Liver Physiol,2012,302:G343-G351.
[20]	SUZUKI T,YOSHINAGA N,TANABE S.Interleukin-6(IL-6)regulates claudin-2 expression and tight junction permeability in intestinal epithelium[J].J Biol Chem,2011,286:31263-31271.
[21]	AL-SADI R,YE D,SAID H M,et al.IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1activation of canonical NF-kappaB pathway[J].Am J Pathol,2010,177:2310-2322.
[22]	PICKERT G,NEUFERT C,LEPPKES M,et al.STAT3links IL-22 signaling in intestinal epithelial cells to mucosal wound healing[J].J Exp Med,2009,206:1465-1472.
[23]	ZHENG Y,VALDEZ P A,DANILENKO D M,et al.Interleukin-22mediates early host defense against attaching and effacing bacterial pathogens[J].Nat Med,2008,14:282-289.
[24]	DABEK M,FERRIER L,ANNAHAZI A,et al.Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice:role of cathepsin G and protease-activated receptor-4[J].Inflamm Bowel Dis,2011,17:1409-1414.
[25]	AL-SADI R,BOIVIN M,Ma T.Mechanism of cytokine modulation of epithelial tight junction barrier[J].Front Biosci(Landmark Ed),2009,14:2765-2778.
[26]	JOWETT S L,SEAL C J,PEARCE M S,et al.Influence of dietary factors on the clinical course of ulcerative colitis:aprospective cohort study[J].Gut,2004,53:1479-1484.
[27]	NEGRONI A,COSTANZO M,VITALI R,et al.Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2012,18:913-924.
[28]	MOOSSAVI S,ZHANG H,SUN J,et al.Host-microbiota interaction and intestinal stem cells in chronic inflammation and colorectal cancer[J].Expert Rev Clin Immunol,2013,9:409-422.
[29]	MONTROSE D C,SCHERL E J,BOSWORTH B P,et al.S1P(1)localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity[J].J Lipid Res,2013,54:843-851.
[30]	HATOUM O A,MIURA H,BINION D G.The vascular contribution in the pathogenesis of inflammatory bowel disease[J].Am J Physiol Heart Circ Physiol,2003,285:H1791-H1796.
[31]	CHIDLOW J H,Jr.,SHUKLA D,GRISHAM M B,et al.Pathogenic angiogenesis in IBD and experimental colitis:new ideas and therapeutic avenues[J].Am J Physiol Gastrointest Liver Physiol,2007,293:G5-G18.
[32]	CHIDLOW J H,Jr.,LANGSTON W,GREER J J,et al.Differential angiogenic regulation of experimental colitis[J].Am J Pathol,2006,169:2014-2030.
[33]	DENG X,SZABO S,KHOMENKO T,et al.Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis[J].Curr Pharm Des,2013,19:17-28.